Heart failure & cardiomyopathiesDiagnostic or prognostic study
Expansion of the National Amyloidosis Centre Staging System to Detect Early Mortality in Transthyretin Cardiac Amyloidosis
- Prognostic cohort study
Optimal NT-proBNP cut-point from time-dependent ROC curves in National Amyloidosis Centre (NAC) stage 3 subgroup
Authors' conclusion
The proposed modification of the NAC staging system identifies patients with ATTR-CA at a high risk of early mortality
Study context
- Population
- Patients with transthyretin cardiac amyloidosis (ATTR-CA)
- Participants
- 2,042 patients
- Comparison
- Expanded NAC staging for early mortality
- Stage 1n = 886reference
- Stage 2n = 706
- Stage 3n = 270
- Stage 4n = 180
- Outcome
- Mortality
- Follow-up
- 1 year
Performance
As reported in the abstract
Hazard ratio (95% CI)
Stage 4 vs Stage 1
15.5(9.3–26.1)
Stage 4 vs Stage 3
3.4(2.2–5.4)
- Log-rank across NAC stages
- P < 0.001
Further findings
Early mortality risk by genotype, HF symptom severity and echocardiographic parameters (subgroups)
- Increased risk of early mortality consistent across subgroups
Original publication
Expansion of the National Amyloidosis Centre Staging System to Detect Early Mortality in Transthyretin Cardiac Amyloidosis. Eur J Heart Fail. Published 23 June 2024. doi:10.1002/ejhf.3354
Summarised from the published abstract; every number is checked against it